Abstract:We appreciate the interest in our study1 by Dr Takagi, Dr Umemoto and their team from the Department of Cardiovascular Surgery, Shizuoka Medical Centre, Shizuoka, Japan and we would like to respond. We went through the literature and reviewed many articles on the effect of preoperative statin therapy on postoperative atrial fibrillation (AF) in cardiac surgery patients.2–4 However, we found that much of the research had not really been conducted in patients who had undergone off-pump coronary artery bypass grafting (OPCABG) surgery and received preoperative statin therapy. Therefore, we took the opportunity to conduct such a trial in a domestic Chinese population, especially as AF has genetic heterogeneity and statin therapy has variable effects in different ethnic populations. However, to ensure the trial had an acceptable level of evidence, we devised it in such a way as to remove most of the biases. Consequently, we resorted to a prospective randomized, double-blind placebo-controlled trial in which the patients were randomly divided into a statin or a control group through a computer-generated randomized sequence. This study spanned a 2-year period. The medical practitioners involved in care-giving were unaware of the type of therapy (placebo or statin) the selected patients were getting. The study was conducted in a very specific and well-defined group of patients: those who were undergoing elective OPCABG and who had no history of AF prior to the surgery. Several other inclusion and exclusion criteria were established and were meticulously followed. The inclusion criteria included normal liver and kidney functions, no previous or current statin therapy, and no inflammatory disease requiring any type of anti-inflammatory treatment, which could have interfered with the already established anti-inflammatory properties of statins. Exclusion criteria included adverse reactions of statin therapy on the digestive system, altered liver function, perioperative unstable hemodynamics and/or intra-aortic balloon pump use, and postoperative important organ dysfunction. All possible factors that could have an effect on the result were included. The statin therapy was started 1 week before the elective surgery to allow time for the statin to at least start exerting its effect. The placebo was also begun at that time. In the statin group, patients were administered a daily dose of 20 mg of oral atorvastatin. The cut-off points of the study were well defined and respected. The primary endpoint was the occurrence of postoperative AF, while the secondary endpoints were major cardiac and cerebrovascular events, persistent postoperative in-hospital AF and identification of other parameters predicting postoperative AF. After the elective surgery was performed, occurrence of AF was evaluated through ECG monitoring; initially, each patient had continuous and strict ECG monitoring for at least the first 7 postoperative days and subsequently daily 12-lead ECG monitoring until hospital discharge. The occurrence and duration of postoperative AF, time of postoperative AF occurrence, and the highest ventricular rate were systematically recorded, as were postoperative complications, mortality and adverse responses to atorvastatin. At the onset of postoperative AF, patients received a single loading dose (5 mg/kg, maximum 300 mg) of intravenous amiodarone as a bolus over 30 min, followed by continuous amiodarone infusion at a rate of 0.5 mg · kg–1 · h−1. Another parameter, C-reactive protein (CRP), which is a marker of systemic inflammation, was also assessed. Measurements were carried out several times for each patient, the first before the operation and then every 24 h following surgery until discharge from hospital. Analysis of the collected data was performed using several testing options of the commercially available statistical software program SPSS 13.0. Preand perioperative independent variables were determined and their individual effects on the incidence of postoperative AF were calculated. In our study the independent risk factors for occurrence of AF after OPCABG were preoperative atorvastatin therapy, postoperative CRP level above the median value, age over 65, and proximal and middle lesions of the right coronary arteries. So, from our study we reached the conclusion that preoperative administration of a statin did significantly reduce the incidence of AF after elective OPCABG. However, our study included only moderate-risk patients. It remains to be determined if high-risk surgical patients may benefit more from preoperative administration of a statin.

ASSA13-02-16 Atorvastatin Therapy in Patients with Atrial Fibrillation Ablation to Maintain Sinus Rhythm

GW24-e0428 Atorvastatin therapy in patients with atrial fibrillation ablation to maintain sinus rhythm

Atorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation: a double-blind, placebo-controlled, randomized trial

The efficacy of high-dose atorvastatin on early recurrence after catheter ablation for paroxysmal atrial fibrillation

Effect of Simvastatin on Acute Coronary Syndrome Complicated with Atrial Fibrillation

Evaluation of rosuvastatin in preventing early recurrence of persistent atrial fibrillation after catheter ablation treatment

Effects of Atorvastatin on Inflammatory Level and Clinical Prognosis in Patients with Chronic Congestive Heart Failure and Paroxysmal Atrial Fibrillation

Role of Preoperative Atorvastatin Administration in Protection Against Postoperative Atrial Fibrillation Following Conventional Coronary Artery Bypass Grafting

Effect of atorvastatin on left atrial function of patients with paroxysmal atrial fibrillation

Effect of Preoperative Atorvastatin Therapy on Atrial Fibrillation Following Off-Pump Coronary Artery Bypass Grafting

[Effect of Atorvastatin on Postoperative Atrial Fibrillation in Patients Undergoing Coronary Artery Bypass Grafting].

Efficacy and Safety of Serial Atorvastatin Load in Chinese Patients Undergoing Elective Percutaneous Coronary Intervention: Results of the ISCAP (intensive Statin Therapy for Chinese Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention) Randomized Controlled Trial

The long-term usage of statin prevents adverse events in patients with atrial fibrillation

Clinical Observation on Efficacy of Irbesartan Combined with Atorvastatin in Treatment of Hyper-tension Complicated with Paroxysmal Atrial Fibrillation

Early and extensive use of statins in patients with acute coronary syndrome

Long-term benefits of high-intensity atorvastatin therapy in Chinese acute coronary syndrome patients undergoing percutaneous coronary intervention: A retrospective study.

Fluvastatin Combined with Benazepril May Contribute to FavorablePrognosis of Auricular Fibrillation

Effects of atorvastatin on the levels of plasma lysophospholipids and the incidence of stroke in patients with atrial fibrillation

Effect of Preoperative Statin Therapy on Postoperative Atrial Fibrillation in Cardiac Surgery

Effect of rosuvastatin on the prognosis of patients with acute myocardial infarction complicated with atrial fibrillation

Impact of duration and dosage of statin treatment and epicardial fat thickness on the recurrence of atrial fibrillation after electrical cardioversion